Answers are grounded in this paper and cite their sources.
Case-control study reveals elevated serum HMGB1 levels across alopecia areata, vitiligo, and oral lichen planus, indicating its utility as a shared inflammatory biomarker.
Background High-mobility group box 1 (HMGB1) may play an important role in autoimmune and inflammatory disorders. Objective To estimate serum levels of HMGB1 in alopecia areata (AA), vitiligo and oral lichen planus (OLP) patients compared with those in normal control subjects. Patients and methods This case-control study consisted of 80 age-matched and sex-matched participants divided into four groups as follows: group I (AA group): 20 AA patients, group II: 20 vitiligo patients, group III: 13 OLP patients, and group IV: 27 healthy controls. Disease severity was assessed based on the severity of Alopecia Tool, Vitiligo Area Scoring Index, and Reticulation Erythema and Ulceration scores. Disease activity/stability was considered for every patient. Serum HMGB1 levels were assessed using a human (HMGB1) ELISA kit for all study participants. Results The levels of serum HMGB1 in groups I, II, and III were significantly higher than those in group IV ( P <0.001). A positive correlation was found between serum HMGB1 levels and severity of Alopecia Tool, Vitiligo Area Scoring Index, and Reticulation, Erythema, and Ulceration severity scores. Serum HMGB1 levels were higher in active AA patients than in stable AA patients; however, no association was found with vitiligo or OLP stability. Conclusion We concluded that serum HMGB1 may serve as a biomarker for AA, vitiligo, and OLP.
No takes yet. Share an insight, caveat, or question.
ElGhareeb et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: